Research
Hormonal
Semaglutide (2.4 mg subcutaneous once weekly) produces significant weight loss in adults with obesity or overweight by reducing appetite and energy intake rather than increasing energy expenditure.
Semaglutide 2.4 mg injected once weekly, combined with lifestyle changes, leads to substantial weight loss (approx 15%) in adults with obesity. The primary mechanism is reduced appetite and food cravings, not increased metabolism. Be prepared for potential nausea, which is the most common reason people stop treatment.
StrongSupportsHIGH confidence
A decrease in appetite and craving for food, a relatively low proclivity for fatty, energy‐rich foods, and better control of eating are the most likely mechanisms for semaglutide-induced weight loss
Why this rating
Based on a systematic review of 12 RCTs including large sample sizes (up to 3297 participants).
Source
Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs)
Mahvish Anam et al. · Cureus · 2022
systematic_reviewCited 35×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →